Donate
Scientists used patient-derived cells to model pyridoxine-dependent epilepsy (PDE-ALDH7A1) and found that dialing down an upstream enzyme (AASS) eased several stress signals in the cells, pointing to a potential new therapy direction.
PDE-ALDH7A1 is a rare metabolic epilepsy where the brain is exposed to a build-up of lysine-pathway byproducts that can disrupt vitamin B6 biology (specifically the active form, PLP) and harm developing brain function. Today’s care often includes vitamin B6 and diet-based approaches, which can help seizures but may not fully prevent learning and development challenges.
In this study, researchers made astrocytes (a key “helper” cell type in the brain) from patient-derived stem cells. They confirmed the expected biochemical fingerprint of PDE and found patterns consistent with oxidative stress and mitochondrial dysfunction. Then they reduced activity of AASS (the first step in lysine breakdown) using gene editing or antisense oligonucleotides (AONs). Those interventions reduced the PDE-like cellular problems, supporting the idea that “upstream” control of lysine metabolism could lower neurotoxic metabolite exposure.
Why this matters
This work connects the dots from PDE biochemistry to measurable stress inside human brain-relevant cells, and it tests a concrete strategy (AASS downregulation) that could complement existing treatments by reducing the toxic load earlier in the pathway.
Limitations
This is a laboratory cell-model study, not a clinical trial. Improvements were measured in patient-derived astrocytes, which is encouraging, but it does not yet show safety or benefit in people with PDE.
Sources
- Schuurmans IME et al. “Targeting AASS alleviates neurotoxicity and improves mitochondrial function in astrocyte models for pyridoxine-dependent epilepsy.” Molecular Therapy – Nucleic Acids (2025). DOI: 10.1016/j.omtn.2025.102728 (PubMed: 41158987; Free full text: PMC12554910)
Safety note: This summary is educational and not medical advice.
